Is MediWound Ltd. overvalued or undervalued?
As of August 6, 2020, MediWound Ltd. is considered overvalued and risky due to poor financial metrics, including a high Price to Book Value of 7.46 and negative EV to EBIT and EV to EBITDA ratios, indicating significant struggles compared to its peers.
As of 6 August 2020, the valuation grade for MediWound Ltd. changed from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 7.46, an EV to EBIT of -9.39, and an EV to EBITDA of -10.10. These ratios suggest that the company's valuation does not align with its current financial performance.In comparison to its peers, MediWound Ltd. has a worse EV to EBITDA ratio than Esperion Therapeutics, Inc. at -28.9150 and a higher Price to Book Value than Oramed Pharmaceuticals, Inc. at 0.2489. The negative ROE of -67.86% further underscores the company's struggles relative to its industry. While recent stock performance data is not available for a direct comparison with the S&P 500, the overall financial indicators suggest that MediWound Ltd. is currently overvalued.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
